The Global Impact of NICE Decision Outcomes in Health Technology Assessment

By HEOR Staff Writer

September 27, 2023

The English National Institute for Health and Care Excellence (NICE) is a key player in Health Technology Assessment (HTA) worldwide. A report from the Office of Health Economics (OHE) explored NICE’s decision outcomes and their effects on HTA in 12 other countries.

Data showed that NICE decisions are issued relatively quickly, often favouring positive outcomes. However, NICE frequently issued “optimised decisions,” recommendations for using an intervention in a smaller population than licensed but with more favourable cost-effectiveness evidence.

The report also found that NICE’s decisions have a global impact. But, the underlying factors may be more influential than individual technology decisions. NICE’s influence often comes from factors like its reputation as a methods innovator, its decision speed, and the accessibility of its guidance. 

NICE decisions have varying degrees of influence on HTA bodies across different countries:

  • In South Korea, NICE’s decisions significantly impact the Health Insurance Review and Assessment Service (HIRA), with external stakeholder groups pressuring HIRA to follow positive NICE recommendations. 
  • In Brazil, NICE’s decisions also have a strong influence on the National Committee for Health Technology Incorporation (Conitec). 
  • In Poland, positive NICE decisions do not greatly impact local reimbursement decisions, but negative decisions or issues with the economic model require further validation. 
  • In Sweden, the Dental and Pharmaceutical Benefits Agency (TLV) considers NICE’s guidance but makes independent decisions. 
  • In Japan, NICE’s decisions are requested by the Central Social Insurance Medical Council (Chuikyo), but their use and influence are unclear. 
  • In Italy, the Italian Medicines Agency (AIFA) does not usually consider NICE’s decisions but may refer to technical points raised during NICE’s appraisal for complex cases. 
  • In Saudi Arabia and the UAE, the Ministry of Health may look at NICE’s decision for context, and in Israel, NICE’s decisions serve as a reference. 


While positive NICE decisions are associated with positive outcomes in other countries, negative decisions stand out. Other HTA agencies are less willing to go beyond binary decision outcomes, making NICE’s negative decisions more noticeable.

The future impact of NICE on the global HTA landscape might change due to increased collaborations between HTA agencies and post-Brexit activities.

Reference url

Recent Posts

CHMP recommendations 2026
CHMP Recommendations 2026: New Approvals and Implications for Health Economics

By HEOR Staff Writer

May 25, 2026

The CHMP recommendations 2026 from the 18–21 May meeting delivered eight positive opinions for new medicines, thirteen extensions of therapeutic indications, and one negative opinion. These decisions bring meaningful progress in areas with significant unmet need, most notably idiopathic pulmonary...
clinical trial monitoring
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

By HEOR Staff Writer

May 22, 2026

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decisi...
Novartis oncology advancements
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...